PROTOKOLwiki
COMPOUNDS / SARM / SR9009
SARM

SR9009

MEDIUM RISK
BEST FOR:Endurance●●●●○○○○○○4/10
SR9009 · STENABOLIC · SR-9009 · REV-ERB AGONIST SR9009
SARMREV-ERBCircadianEnduranceResearch ChemicalWADA Banned

Synthetic REV-ERBα/β agonist affecting circadian metabolism, endurance, and lipid oxidation; not a true SARM despite grey-market classification.

ROUTE / DOSAGE
LOW10mg
STANDARD20-30mg
HIGH40mg+
Note: Poor oral bioavailability; often split into 2-3 daily doses due to short half-life
CYCLE
4-8 weeks 2-3x daily dosing due to short half-life 4-week break recommended between cycles
BIOAVAILABILITY
low oral (~5%) higher via subq/im injection
ACTIVE DURATION
4-8h (subjective)
STORAGE
Room temperature dry away from light refrigerate reconstituted injectable solutions
HALF-LIFE
~4h (plasma)
DURATION BREAKDOWN
Total8-12h
Onset1-2h
Come up1-2h
Peak2-4h
Offset2-4h
After effects4-8h
Duration varies by route, dose, and individual. Source: community reports.
§ 01 — EFFECTS
6 documented
Increased endurance capacity
Enhanced fat oxidation
Reduced lipid synthesis
Altered circadian gene expression
Anti-inflammatory effects
Modulated glucose metabolism
§ 02 — RISKS
No human safety data exists; all findings are from animal and in vitro studies
REV-ERB-independent off-target effects on cell viability and metabolism raise unknown long-term risks
Short half-life requires frequent dosing, increasing cumulative exposure
Potential disruption of natural circadian rhythms with chronic use
WADA-prohibited substance; athletic use results in disqualification
Hepatic and renal effects unknown in humans
§ 03 — INTERACTIONS
Interaction data not yet available for this compound.
§ 04 — SCIENCE

SR9009 was developed by Burris et al. and showed increased exercise endurance and fat loss in mouse models, generating significant grey-market interest. Animal studies demonstrate cardioprotective effects under pressure overload, anti-tumor activity in small-cell lung cancer and prostate cancer, and anti-inflammatory effects in sepsis-induced lung injury. Critically, a 2019 PNAS study showed SR9009 exerts REV-ERB-independent effects on cell proliferation and metabolism, meaning some observed benefits may not reflect REV-ERB agonism. No human clinical trials have been published; all efficacy and safety data derive from in vitro and animal models. The compound is on the WADA Prohibited List and has no approved medical use.

§ 06 — SOURCES
[1]
SR9009 improves heart function after pressure overload independent of cardiac REV-ERB
pubmed.ncbi.nlm.nih.gov ↗
[2]
SR9009 inhibits lethal prostate cancer subtype 1 by regulating the LXRα/FOXM1 pathway independently of REV-ERBs
pubmed.ncbi.nlm.nih.gov ↗
[3]
SR9009 Regulates Acute Lung Injury in Mice Induced by Sepsis
pubmed.ncbi.nlm.nih.gov ↗
[4]
SR9009 has REV-ERB-independent effects on cell proliferation and metabolism
pubmed.ncbi.nlm.nih.gov ↗
[5]
REV-ERBα Agonist SR9009 Promotes a Negative Energy Balance in Goldfish
pubmed.ncbi.nlm.nih.gov ↗
[6]
SR9009 attenuates inflammation-related NPMSC pyroptosis and IVDD through NR1D1/NLRP3/IL-1β pathway (RETRACTED)
pubmed.ncbi.nlm.nih.gov ↗
[7]
SR9009 induces a REV-ERB dependent anti-small-cell lung cancer effect through inhibition of autophagy
pubmed.ncbi.nlm.nih.gov ↗
[8]
Rev-erbα agonist SR9009 protects against cerebral ischemic injury through mechanisms involving Nrf2 pathway
pubmed.ncbi.nlm.nih.gov ↗
Disclaimer. Protokol.wiki is an informational reference. Nothing on this site is medical advice. Compounds listed may be unapproved, unregulated, or illegal in your jurisdiction. Consult a licensed physician before use. Data compiled from peer-reviewed literature.
METHODOLOGYCONTRIBUTECONTACT